Skip to main content
. 1999 Jun;67(6):2964–2968. doi: 10.1128/iai.67.6.2964-2968.1999

FIG. 2.

FIG. 2

FIG. 2

FIG. 2

(A) Binding of serum-pretreated FITC-labeled B. subtilis to human CD14 expressed on CHO cells. Cells were incubated with labeled bacteria in the presence or absence of 1 μg of recombinant LBP per ml. Binding in the presence of LBP is abolished by inclusion of (i) a 20-fold excess of serum-pretreated unlabeled B. subtilis cells, (ii) Salmonella minnesota Re 595 LPS at a final concentration of 20 μg/ml, or (iii) 10 μg of anti CD14 MAb My4 per ml (but not by the same amount of an isotype-matched control). The ratio of cells to bacteria was 1:20. (B) Binding of plasma-pretreated FITC-labeled B. subtilis to human CD14 expressed on CHO cells. B. subtilis organisms were not pretreated (upper), pretreated with serum (middle), or pretreated with plasma (lower). Binding to CHO cells expressing human CD14 was determined in the presence of 1 μg of recombinant LBP per ml. (C) B. subtilis does not bind to the mutant CD14(39–41, 43–44A), which lacks the binding sites for LPS and E. coli.